Ciphergen study finds biomarkers distinguish ovarian cancer

New York, June 5 - Ciphergen Biosystems, Inc. announced that a multi-center study evaluating a set of seven biomarkers for the detection of ovarian cancer found that each biomarker individually demonstrated statistically significant power to differentiate ovarian cancer patients from women with benign disease.

As in previous studies, an index derived from the seven markers demonstrated improved specificity for discriminating ovarian cancer from benign pelvic masses, as well as for the detection of early stage cancer.

This is the first time that biomarkers discovered through current clinical proteomics efforts have been subjected to a large-scale multi-institutional independent validation study, Ciphergen said.

The trial included 607 patient samples taken from five international medical centers. Of the total, 234 women had benign gynecologic disease and 373 patients had invasive epithelial ovarian cancer, including 101 with early stage cancer.

The results were presented at the annual meeting of the American Society of Clinical Oncology.

Fremont, Calif.-based Ciphergen is dedicated to translating protein biomarkers and panels of biomarkers into protein molecular diagnostic tests that improve patient care.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.